Nugroho Pringgodigdo, Hidayat Nur, Harimurti Kuntjoro, Rinaldi Ikhwan, Tenda Eric Daniel, Rachman Andhika, Kusumo Wibowo Suryo Anggoro
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Int J Nephrol Renovasc Dis. 2025 Jun 10;18:151-162. doi: 10.2147/IJNRD.S513968. eCollection 2025.
Patients with Chronic Kidney Disease (CKD) undergoing regular hemodialysis experience various metabolic changes, including premature aging marked by increased prevalence of frailty. Beta-2 microglobulin (B2M), a uremic toxin whose concentration significantly increases in hemodialysis patients, has emerged as a potential biomarker of frailty. Previous evidence suggests potential link between B2M and frailty in older adults. However, data on its relationship with frailty in hemodialysis patients remains limited.
To determine the relationship between B2M concentration and frailty in hemodialysis patients.
This is a cross-sectional study utilizing primary data from hemodialysis patients at Rumah Sakit Cipto Mangunkusumo (RSCM), employing a total sampling method. Beta-2 microglobulin was measured using the Enzyme-Linked Fluorescent Assay (ELFA) method. Frailty was assessed using the Frailty Index 40-item. Medical history was obtained from medical records and interviews. Chi-square tests were performed to determine the relationship between B2M and frailty. Multivariate analysis was conducted to determine variables that affect frailty.
A total of 79 subjects participated in the study. The median B2M concentration was 32.8 (IQR 29.8-36.77). Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69-33.81, p = 0.113). The final multivariate analysis showed that sarcopenia (PR 5.37; 95% CI 2.88-10.04) was strongly and consistently associated with frailty prevalence.
Higher B2M showed a trend towards increased frailty prevalence; however, this association is not statistically significant. Sarcopenia is a significant factor influencing the prevalence of frailty in hemodialysis patients.
接受定期血液透析的慢性肾脏病（CKD）患者会经历各种代谢变化，包括以虚弱患病率增加为特征的早衰。β2微球蛋白（B2M）是一种尿毒症毒素，其浓度在血液透析患者中显著升高，已成为虚弱的潜在生物标志物。先前的证据表明B2M与老年人虚弱之间存在潜在联系。然而，关于其与血液透析患者虚弱关系的数据仍然有限。
确定血液透析患者B2M浓度与虚弱之间的关系。
这是一项横断面研究，利用西爪哇省芝多阿医院（RSCM）血液透析患者的原始数据，采用全样本抽样方法。使用酶联荧光分析法（ELFA）测量β2微球蛋白。使用40项虚弱指数评估虚弱情况。通过病历和访谈获取病史。进行卡方检验以确定B2M与虚弱之间的关系。进行多变量分析以确定影响虚弱的变量。
共有79名受试者参与研究。B2M浓度中位数为32.8（四分位间距29.8 - 36.77）。较高的B2M浓度显示出虚弱患病率增加的趋势（患病率比值为4.83，95%置信区间0.69 - 33.81，p = 0.113）。最终的多变量分析表明，肌肉减少症（患病率比值5.37；95%置信区间2.88 - 10.04）与虚弱患病率密切且持续相关。
较高的B2M显示出虚弱患病率增加的趋势；然而，这种关联在统计学上并不显著。肌肉减少症是影响血液透析患者虚弱患病率的重要因素。
